Open biotechnology may be the ideal solution to ensure scientific progress and the realization of the common good, but it has yet to deliver on its promises.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Stem Cell Research Funding Policies and Dynamic Innovation: A Survey of Open Access and Commercialization Requirements
Stem Cell Reviews and Reports Open Access 28 March 2014
-
Open science versus commercialization: a modern research conflict?
Genome Medicine Open Access 27 February 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Boyle, J. in Perspectives on Properties of the Human Genome Project (ed. Kieff, F.S.) 97 (Elsevier Academic Press, St. Louis, USA 2003).
Heller, M.A. & Eisenberg, R.S. Science 280, 698–701 (1998).
Merges, R.P. & Nelson, R. Columbia Law Rev. 90, 839–916 (1990).
Kass, L. Toward a More Natural Science (Free Press, New York, 1985).
Kass, L. Public Interest 107, 65–86 (1992).
Greenfield, D. Santa Clara Comput. High Technol. Law J. 25, 467–538 (2009).
Caulfield, T., Cook-Deegan, R.M., Kieff, F.S. & Walsh, J.P. Nat. Biotechnol. 24, 1091–1094 (2006).
Cho, M.K., Illangasekare, S., Weaver, M.A., Leonard, D.G.B. & Merz, J.F. J. Mol. Diagn. 5, 3–8 (2003).
Matthijs, G. & Halley, D. Eur. J. Hum. Genet. 10, 783–785 (2002).
Murray, F. N. Engl. J. Med. 356, 2341–2343 (2007).
St.-Laurent, A.M. Understanding Open Source and Free Software Licensing, (O'Reilly Publishing, Sebastopol, California, 2004).
Curry v. Audax, District Court of Amsterdam Case no. 334492/KG 06–176 SR (2006).
Jacobsen v. Katzer, 535 F.3d 1373 (Fed. Cir. 2008).
In re: Dane K. Fisher and Rughunath v. Lalgudi 421 F.3d 1365 (Fed Cir. 2005).
In re: Marek Z. Kubin and Raymond G. Goodwin No. 09–667,859 (Fed. Cir. April 3, 2009).
US General Accounting Offices. Report to Congressional Requesters (GAO-02–789) (US General Accounting Offices, Washington, DC, 2002).
Malakoff, D. Science 291, 1194 (2001).
Guadamuz Gonzàlez, A. NCJL & Tech. 7, 321–366 (2006).
Data Access Policy for the International HapMap Project (policy no longer in use). http://hapmap.ncbi.nlm.nih.gov/cgi-perl/registration
Wellcome Trust Case Control Consortium. https://www.wtccc.org.uk/info/access_to_data_samples.shtml
Cromer, J.D. UMKC Law Rev. 76, 505–523 (2007).
Birney, E. et al. Nature 461, 168–170 (2009).
Cottrell, C.R. Wake Forest Intell. Prop. L.J. 7, 251–274 (2007).
Acknowledgements
The author would like to thank F. Hemmings and B.M. Knoppers for reviewing the manuscript, E.R. Gold for comments on an earlier version of the draft and Genome Canada/Genome Quebec for their financial support of the PRIVAC project Genomics Applied to the Discovery and Development of Vaccines and Immunotherapies.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Joly, Y. Open biotechnology: licenses needed. Nat Biotechnol 28, 417–419 (2010). https://doi.org/10.1038/nbt0510-417
Issue Date:
DOI: https://doi.org/10.1038/nbt0510-417
This article is cited by
-
Stem Cell Research Funding Policies and Dynamic Innovation: A Survey of Open Access and Commercialization Requirements
Stem Cell Reviews and Reports (2014)
-
Open science versus commercialization: a modern research conflict?
Genome Medicine (2012)
-
Translational Bioinformatics: Data-driven Drug Discovery and Development
Clinical Pharmacology & Therapeutics (2012)
-
Theory of knowledge and biotech patents: worlds apart?
Nature Biotechnology (2011)